Corporate Social Responsibility (CSR)
By providing non-clinical trials, we accelerate the drug development process and assist in delivering new drugs to patients as quickly as possible.

At SMC Laboratories, we work with a strong awareness of Sustainable Development Goals (SDGs), Corporate Social Responsibility (CSR).


Development goals addressed by SMC Laboratories

Development goals addressed by SMC Laboratories
The Sustainable Development Goals (SDGs), adopted by the United Nations General Assembly in 2015, are 17 global goals to be achieved by 2030.
Of the 17 goals, Goals 3 and 9 are the most important goals directly linked to the business of SMC Laboratories, Inc.
We are contributing to the achievement of the SDGs, centering on the two goals that form the basis of our business activities.



We are contributing to the development of innovative new drugs aimed at treating diseases with high unmet medical needs. By providing non-pharmacological studies using the STAM™ model, a steatohepatitis (metabolic dysfunction-associated steatohepatitis (MASH,f.k.a. NASH) mouse model, and pathological model mice with high clinical correlation, we accelerate the development process of new drugs. We aim to help deliver new medicines to patients as soon as possible.



We are engaged in research and development of a non-clinical pharmacological evaluation study system for the creation of new drugs for diseases with high unmet medical needs. In particular, we are actively investing in research and development in the fields of liver and lung diseases.
We have acquired new data such as biomarkers, which are attracting clinical attention, to the STAM™ model, which is a globally recognized MASH/NASH model, and are proceeding with further development as a model with high clinical correlation. Along with the MASH/NASH and idiopathic pulmonary fibrosis models that we have focused on, we are also developing models for pneumonia, which has become more prevalent due to the state of viral infections in the world today. We have developed a model of viral pneumonia and its prognosis, the process leading to fibrosis, which develops through a mechanism similar to ones in clinical practice. We have begun to provide the model to our clients.

オリジナル病態動物モデルSTAM™マウス (MASH/NASH モデル)

Our original model
STAM™ mouse (MASH/NASH-HCC model)


Our company aims to support and develop the qualifications and abilities of our employees through qualification-based incentives and various training systems. Specifically, we hire from a wide range of countries and provide language skills support and qualification-based incentives for those with a rich international mindset, as well as training and various qualification-based incentives for researchers who require specialized skills. In order to acquire a wide range of knowledge, we also participate in domestic and international academic conferences, as well as conduct and promote overseas training with affiliated companies.



We are actively engaged in job creation and continually hire new graduates as well as mid-career professionals. As a company, we are committed to supporting the growth of the Japanese economy by expanding our business.


Animal welfare by SMC Laboratories

Approach to experimental animal welfare

SMC Laboratories is working to contribute to the health and prosperity of humankind by supporting drug development worldwide. Animal experiments are indispensable for the research and development of pharmaceuticals, and we are working to improve animal welfare based on the recognition that animals are living creatures.
When handling experimental animals, we have established "Animal Experiment Regulations" that comply with the following animal welfare-related Japanese laws and regulations, and strive to use them properly based on the principles of the 3Rs.
*Refinement: Relief of pain, Replacement: Use of alternative methods, Reduction: Reduction of animal usage

Animal welfare related regulations

We carry out animal experiments in compliance with the applicable Japanese laws and regulations as follows.

  • Act on Welfare and Management of Animals
    (Ministry of the Environment, Act No. 105 of October 1, 1973)
  • Standards Relating to the Care and Management of Laboratory Animals and Relief of Pain (Notice No.88 of the Ministry of the Environment, April 28, 2006)
  • Basic guidelines for the conduct of animal experiments in implementing agencies under the jurisdiction of the ministry of health, labor and welfare
    (Ministry of Health, Labor, and Welfare, June 1, 2006)
  • The basic policy on measures that should be implemented with regard to the welfare and management of animals
    (Ministry of the Environment, 2006)
  • Standards relating to the Methods of Destruction of Animals
    (Notice of the Ministry of the Environment, November 12, 2007)
  • Guidelines for Proper Conduct of Animal Experiments
    (Science Council of Japan, June 1, 2006)
  • Guide for the Care and Use of Laboratory Animals; Eighth Edition(National Research Council, 2011)

The principles of the 3Rs (Replacement, Reduction and Refinement)

We are working to improve animal welfare by preparing and implementing appropriate animal experiment plans based on the 3Rs principle.

  • Refinement; use of methods that alleviate or minimize potential pain
    Pain relief, euthanasia, improvement of breeding einvironment, etc
  • Replacement; methods which avoid or replace the use of animals in experiments
    In vitro tests as alternatives, elimination of duplicate experiments, etc.
  • Reduction; reduce the number of animals used as much as possible
    Reduce the number of animals used, use the minimum number of animals scientifically required, etc.